甲状腺切除术后超重与肥胖患者的甲状腺激素替代剂量评估
该回顾性研究纳入114例全甲状腺切除术后经甲状腺激素替代(THR)达到甲状腺功能正常的患者,评估不同BMI下的左甲状腺素(LT4)适宜剂量。结果显示,基于体重的传统给药方式使35%的肥胖患者初始剂量过量,达到甲状腺功能正常所需LT4剂量随BMI升高而相对体重降低。
要点
- 肥胖患者初始LT4剂量过量比例达35%,基于体重的给药方式不适当。
- 达到甲状腺功能正常所需LT4剂量(mcg/kg)随BMI升高而显著降低。
- LT4滴定公式应同时考虑体重和BMI。
核心结论
- 当前基于体重的THR给药方式使超重和肥胖患者剂量过量。
- 更合适的THR滴定公式应同时考虑患者体重和BMI。
研究设计与样本
- 回顾性研究,纳入114例全甲状腺切除术后良性诊断且经THR达到甲状腺功能正常的患者。
- 平均年龄55岁(范围28-77岁),84%为女性。
主要发现
- BMI<25、25-29、30-34、35-39、>40的患者分别为26例(23%)、33例(29%)、23例(20%)、19例(17%)、13例(11%)。
- 整个队列达到甲状腺功能正常平均历时50周,不同BMI类别间无显著差异(p=0.58)。
- 肥胖患者(BMI>30)中35%初始LT4剂量过量。
- 队列达到甲状腺功能正常期间平均体重下降3 kg,不同BMI类别间体重下降无显著差异(p=0.61)。
- BMI更高的患者需要更高剂量(mcg)的LT4达到甲状腺功能正常(p<0.01),但按体重计算的剂量(mcg/kg)显著更低(p<0.01)。
关键数值与推荐
- 按BMI<25、25-29、30-34、35-39、>40分组,达到甲状腺功能正常所需LT4剂量分别为1.76、1.47、1.42、1.27、1.28 mcg/kg。
临床怎么用
- 对超重和肥胖患者启动THR时应避免单纯基于体重的剂量,以减少过量风险。
- LT4剂量滴定应结合体重和BMI,并密切监测甲状腺功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Initiation of thyroid hormone replacement (THR) after a total thyroidectomy has traditionally relied on the weight of the patient, regardless of the patient's body mass index (BMI). Current literature suggests that THR in obese patients differs from nonobese patients. This can lead to overdosing of levothyroxine (LT4) and delay in achievement of euthyroid state. Methods: We retrospectively identified patients on THR after total thyroidectomy with a benign postoperative diagnosis. Patients who achieved euthyroidism with THR were included in the analysis. Patient demographic and THR dosing information was collected. Regression analysis was performed to identify appropriate THR dosing at varying BMIs. This study aimed to evaluate the appropriate dosing of THR in overweight and obese patients. Results: Our cohort consisted of 114 patients achieving euthyroidism while on THR. Mean age was 55 years (range 28-77 years) with 84% females. Of the 114 patients, the number of patients with a BMI less than 25, 25-29, 30-34, 35-39, and greater than 40 were 26 (23%), 33 (29%), 23 (20%), 19 (17%), and 13 (11%), respectively. Of the entire cohort, a mean of 50 weeks elapsed after surgery to achieve euthyroidism, with no significant difference between the BMI categories (p = 0.58). In obese patients (BMI >30), 35% were overdosed with LT4 on initial dosing. The cohort lost a mean of 3 kg until euthyroidism was achieved, with no significant difference in the weight loss based on BMI category (p = 0.61). Patients with a higher BMI did require a higher dose (mcg) of LT4 to achieve euthyroidism (p < 0.01), but the dose was significantly lower in relation to their weight (mcg/kg) (p < 0.01). The LT4 dose required to achieve euthyroidism based on the previously mentioned BMI categories were 1.76, 1.47, 1.42, 1.27, and 1.28 mcg/kg. Conclusion: The current weight-based dosing of THR inappropriately overdoses overweight and obese patients. A more appropriate formula for THR titration should consider both the weight and BMI of the patient.
引用
- Papoian V, Ylli D, Felger EA, et al. Evaluation of Thyroid Hormone Replacement Dosing in Overweight and Obese Patients After a Thyroidectomy. Thyroid. 2019. PMID: 31573413. doi:10.1089/thy.2019.0251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。